Douglas Doerfler - 03 Jan 2023 Form 4 Insider Report for MAXCYTE, INC. (MXCT)

Role
President and CEO, Director
Signature
/s/ Brian F. Leaf, attorney-in-fact
Issuer symbol
MXCT
Transactions as of
03 Jan 2023
Transactions value $
-$151,230
Form type
4
Filing time
05 Jan 2023, 16:39:02 UTC
Previous filing
29 Mar 2022
Next filing
03 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction MXCT Common Stock Options Exercise $424 +10,613 +3.2% $0.04* 343,810 03 Jan 2023 Direct F1
transaction MXCT Common Stock Sale -$54,444 -10,613 -3.1% $5.13 333,197 03 Jan 2023 Direct F1, F2
transaction MXCT Common Stock Options Exercise $366 +9,153 +2.7% $0.04* 342,350 04 Jan 2023 Direct F1
transaction MXCT Common Stock Sale -$46,405 -9,153 -2.7% $5.07 333,197 04 Jan 2023 Direct F1, F3
transaction MXCT Common Stock Options Exercise $409 +10,234 +3.1% $0.04* 343,431 05 Jan 2023 Direct F1
transaction MXCT Common Stock Sale -$51,579 -10,234 -3% $5.04 333,197 05 Jan 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction MXCT Employee Stock Option (right to buy) Options Exercise $0 -10,613 -2.4% $0 434,467 03 Jan 2023 Common Stock 10,613 $0.04 Direct F1, F5
transaction MXCT Employee Stock Option (right to buy) Options Exercise $0 -9,153 -2.1% $0 425,314 04 Jan 2023 Common Stock 9,153 $0.04 Direct F1, F5
transaction MXCT Employee Stock Option (right to buy) Options Exercise $0 -10,234 -2.4% $0 415,080 05 Jan 2023 Common Stock 10,234 $0.04 Direct F1, F5
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales and option exercises reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 18, 2022 relating solely to the sale of shares acquired from exercise of an option that expires on November 11, 2024.
F2 The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.49, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F3 The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.19, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F4 The price reported is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.00 to $5.14, inclusive. The reporting person undertakes to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote to this Form 4.
F5 This option is fully vested and exercisable.